Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

TRYP Therapeutics Inc (TRYP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.06 0.00    0.00%
29/04 - Closed. Currency in CAD ( Disclaimer )
Type:  Equity
Market:  Canada
  • Volume: 0
  • Bid/Ask: 0.06 / 0.07
  • Day's Range: 0.06 - 0.06
TRYP Therapeutics 0.06 0.00 0.00%

TRYP Therapeutics (TRYP) Earnings Dates & Reports

 
On this page, you can find detailed information about the financial performance of TRYP Therapeutics Inc, including the latest TRYP Therapeutics Inc earnings report and upcoming earnings date. The page provides an overview of the company's financial health, with key data points such as the current stock price, earnings per share, and revenue compared against the forecast.
InvestingPro Earnings Insights
Latest Release

Apr 27, 2024

EPS / Forecast

-0.01 / -0.01

Revenue / Forecast

-- / 0.00

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Jul 25, 2024 05/2024 -- /  -0.01 -- /  0.00
Apr 27, 2024 02/2024 -0.01 /  -0.01 -- /  0.00
Feb 06, 2024 11/2023 -0.01 /  -0.01 0.00 /  0.00
Jan 01, 2024 08/2023 -0.01 /  -0.02 0.00 /  0.00
Jul 31, 2023 05/2023 -- /  -0.02 -- /  0.00
Apr 28, 2023 02/2023 -0.01 /  -0.01 -- /  0.00
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View upcoming earnings forecasts and in-depth analysis of company forecasts.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TRYP Comments

Write your thoughts about TRYP Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Matty Silverstoone
Matty Silverstoone Jul 23, 2021 12:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By targeting the 505 b2 and the orphan drug design, $TRYP is granted the "Orphan Drug Status", meaning that they receive much shorter review wait times, federal tax credit for clinical trials, and direct written recommendation from the FDA on the trials. They are working to get their psilocybin treatments approved by the FDA and on the market, and recently announced plans for a Phase 2a clinical trial to evaluate the efficacy of TRYP-8802 for treating Fibromyalgia with the University of Michigan. This is one to watch!
Stock Hawk
Stock Hawk Jul 15, 2021 3:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Tryp Therapeutics ( $TRYP ) is a pharmaceutical company focused on developing psilocybin-based compounds. One of their products is in phase 2 of clinical trials to see if it helps fibromyalgia and eating disorder patients. Additionally, they are trying to develop synthetic psilocybin.Today $TRYP.CN announced that they will host their Q3 Investor Day, online, on July 29 at 9:00am PSTDuring this event, Tryp's management team will discuss updates on their synthetic psilocybin programThere will also be a Q&A session with the company's leaders including the CEO, CFO, and PresidentTheir CEO, Greg McKee, stated that he was excited to showcase the research that Tryp has been doing in collaboration with the University of Michigan, the University of Florida, and other academic partnersMore here, as well as a link to register for the event: https://ceo.ca/@newsfile/tryp-therapeutics-to-host-q3-investor-day-on-july-29
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email